WO2004002440A1 - Composition cosmetique pour la peau contenant du melanotan ii et son utilisation en tant que produit de bronzage - Google Patents

Composition cosmetique pour la peau contenant du melanotan ii et son utilisation en tant que produit de bronzage Download PDF

Info

Publication number
WO2004002440A1
WO2004002440A1 PCT/EP2003/006772 EP0306772W WO2004002440A1 WO 2004002440 A1 WO2004002440 A1 WO 2004002440A1 EP 0306772 W EP0306772 W EP 0306772W WO 2004002440 A1 WO2004002440 A1 WO 2004002440A1
Authority
WO
WIPO (PCT)
Prior art keywords
melanotan
composition according
skin
oil
cosmetic composition
Prior art date
Application number
PCT/EP2003/006772
Other languages
German (de)
English (en)
Inventor
Elfriede Rauch
Original Assignee
Elfriede Rauch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elfriede Rauch filed Critical Elfriede Rauch
Priority to AU2003246597A priority Critical patent/AU2003246597A1/en
Publication of WO2004002440A1 publication Critical patent/WO2004002440A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/04—Preparations for care of the skin for chemically tanning the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Definitions

  • the present invention relates to a topically applicable skin cosmetic composition and its use as a skin tanning agent.
  • the natural color of human skin is caused, among other things, by melanin.
  • Melanin is formed in the so-called melanocytes, especially under the influence of sunlight.
  • the hormones melatonin and melanotropin influence the agglomeration or dispersion of the melanin granules in the melanocytes and thus the color of the skin.
  • Melanotan I and Melanotan II are known as synthetic analogues of the melanocyte-stimulating hormone.
  • Melanotan I is a linear oligopeptide that contains all thirteen amino acids of the melanocyte-stimulating hormone.
  • Melanotan II is a shortened cyclic version of the same peptide with the amino acid sequence Leu-Asp-His-Phe-Arg-Trp-Lys.
  • melanotan II can suppress the food stimulus in cases of food addiction and has a neuropeptide effect. Furthermore, Melanotan II shows a melanocytic interference in cell cultures, which has the effect of stimulating melanin production and should consequently stimulate skin tinting when used in vivo.
  • a topically applicable skin cosmetic composition which has an effective melanotan II content in a cosmetically compatible carrier.
  • the side effects associated with oral or intravenous administration of Melanotan II can be safely avoided by topical administration.
  • topical administration it was found that applying Melanotans II to the skin leads to a lasting skin tan even in low concentrations of active ingredient.
  • the topical administration also allows the formulation of a large number of preparations with which the skin condition can be influenced, if necessary, by means of additional active substances.
  • the composition preferably contains between 0.1 and 0.3% by weight of Melanotan II.
  • An active substance content of less than 0.1% requires a longer period of use in order to achieve a visible browning. Shares above 0.3% no longer significantly improve the effect.
  • Melanotan II is particularly preferably in liposomatic solution.
  • One or more phospholipids can be used in a known manner to prepare liposomatic solutions.
  • the use of phosphatidylcholine is particularly preferred.
  • the use of liposomatic solutions enhances the natural appearance of the skin.
  • the cosmetic composition according to the invention can be in the forms commonly used for this type.
  • the cosmetically acceptable carrier can be used as an oily or oil-alcoholic lotion, water-in-oil or oil-in-water emulsion, as a cream or as milk, in the form of oil-alcoholic, oil-water or water-alcohol gels, as a stick or conditioned as an aerosol.
  • composition can also be used as a day cream, night cream, facial care cream, face or body lotion, foam cream or foam mask, hand cream, cleaning cream or lotion, washing cream, facial tonic or Face mask, lip care, skin protection cream, sun protection cosmetics, bath preparation or body oil.
  • compositions can also contain cosmetic auxiliaries which are customary for cosmetic compositions, such as, for example, solvents, thickeners, plasticizers, moisturizers, surface-active agents, preservatives, anti-foaming agents, perfume oils, waxes, lanolin, allantoin, propellants, dyes and / or pigments, UV filters to protect against UV-A and / or UV-B rays and other incidents commonly used in cosmetics, as well as water.
  • cosmetic auxiliaries which are customary for cosmetic compositions, such as, for example, solvents, thickeners, plasticizers, moisturizers, surface-active agents, preservatives, anti-foaming agents, perfume oils, waxes, lanolin, allantoin, propellants, dyes and / or pigments, UV filters to protect against UV-A and / or UV-B rays and other incidents commonly used in cosmetics, as well as water.
  • water, an oil, wax or other fats, a lower monoalcohol or a low polyol or mixtures thereof can be used as solution aids.
  • the particularly preferred monoalcohols or polyols include ethanol, i-propanol, propylene glycol, glycerin and sorbitol.
  • composition in the form of an emulsion, for example cream or milk, it particularly preferably comprises fatty alcohols, fatty acids, fatty acid esters, in particular triglycerides of fatty acids, lanolin, natural or synthetic oils or waxes and emulsifiers in the presence of water.
  • the composition comprises natural or synthetic oils and waxes, lanolin and / or fatty acid esters, in particular triglycerides of fatty acids.
  • the composition comprises a lower alcohol, such as ethanol, a glycol, such as propylene glycol and / or a polyol, such as glycerin, and oils, waxes and fatty acid esters, in particular triglycerides of fatty acids.
  • composition according to the invention can also be present as an alcoholic gel which comprises one or more lower alcohols or polyols, such as ethanol, propylene glycol or glycerol, and a thickener, such as silica.
  • the oily-alcoholic gels also contain natural or synthetic oil or wax.
  • the composition according to the invention can be conditioned as a solid stick and contain natural or synthetic waxes and oils, fatty alcohols, fatty acid esters, lanolin and other fats.
  • Suitable UV filters are, for example, derivatives of cinnamic acid, benzylidene camphor and its derivatives, p-aminobenzoic acid and its derivatives, salicylic acid derivatives, benzophenone derivatives and dibenzoylmethane derivatives.
  • the customary propellants such as alkanes, fluoroalkanes and chlorofluoroalkanes, are used.
  • Suitable thickeners or gelling agents are, for example, goa gum, heterobiopolysaccharides, xanthan gum, scleroglucans, cellulose derivatives, such as, for example, methyl cellulose, hydroxyethyl cellulose, hydroxymethyl propyl cellulose, alkali metal salts of carboxymethyl cellulose, and polyacrylic acids.
  • composition can also contain other active ingredients for the treatment or prevention of skin diseases or for skin improvement, provided that these active ingredients do not influence the action of Melanotan II.
  • a cosmetic composition containing Melanotan II in liposomatic solution was prepared with the following ingredients, the proportions of the ingredients being given in percent by weight:
  • composition so prepared was used to treat five female volunteers between the ages of 25 and 40. It was applied by daily application of the composition to the right forearm. The volunteers were asked to live a normal life, but expose the right and left forearms to sunlight and to avoid wearing long-sleeved clothes. The experiment was carried out in the spring under good climatic conditions and therefore good tanning.
  • the optimum melanotan content determined in the experiments is between 0.1% by weight and 0.3% by weight.
  • the composition can preferably be formulated as a conventional cosmetic emulsion or as a mask preparation. An effective tanning agent is therefore available in a simple dosage form.
  • Example 2
  • the composition is stable and shows a skin-tanning effect.
  • the composition is stable and shows a skin-tanning effect.

Abstract

L'invention concerne une composition cosmétique pour la peau administrable par voie topique et conçue pour être utilisée en tant que produit de bronzage. Cette composition est caractérisée en ce qu'elle contient une quantité efficace de mélatonan II dans un excipient cosmétiquement compatible.
PCT/EP2003/006772 2002-06-27 2003-06-26 Composition cosmetique pour la peau contenant du melanotan ii et son utilisation en tant que produit de bronzage WO2004002440A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003246597A AU2003246597A1 (en) 2002-06-27 2003-06-26 Cosmetic composition for the skin containing melanotan ii and the use thereof as a suntan preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10228837.2 2002-06-27
DE10228837.2A DE10228837B4 (de) 2002-06-27 2002-06-27 Hautkosmetische Zusammensetzung und Verwendung der Zusammensetzung als Hautbräunungsmittel

Publications (1)

Publication Number Publication Date
WO2004002440A1 true WO2004002440A1 (fr) 2004-01-08

Family

ID=29723498

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/006772 WO2004002440A1 (fr) 2002-06-27 2003-06-26 Composition cosmetique pour la peau contenant du melanotan ii et son utilisation en tant que produit de bronzage

Country Status (3)

Country Link
AU (1) AU2003246597A1 (fr)
DE (1) DE10228837B4 (fr)
WO (1) WO2004002440A1 (fr)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1812034A1 (fr) * 2004-10-08 2007-08-01 Clinuvel Pharmaceuticals Limited Prépaprations et méthodes permettant d'induire la mélanogenèse chez un sujet
WO2009124754A1 (fr) * 2008-04-08 2009-10-15 Merck Patent Gmbh Compositions contenant des peptides cycliques et leurs procédés d’utilisation
WO2014160015A1 (fr) * 2013-03-13 2014-10-02 Transdermal Biotechnology, Inc. Compositions pour le bronzage de la peau contenant des peptides et autres compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9585931B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9597401B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9597400B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US10034914B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004623A1 (fr) * 1986-02-03 1987-08-13 University Patents, Inc. Procede de stimulation de melanocytes par l'application topique d'analogues d'alpha-msh, et compositions utilisees
EP0386680A1 (fr) * 1989-03-07 1990-09-12 Plough, Inc. Compositions à base de liposomes
US5641509A (en) * 1992-06-26 1997-06-24 Lancaster Group Ag Preparation for topical use
US5674839A (en) * 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
WO2000004873A1 (fr) * 1998-07-22 2000-02-03 Smith & Nephew Plc Compositions dermatologiques pour le traitement de cicatrices

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3851002T2 (de) * 1987-05-22 1995-02-02 University Patents Inc Lineare und zyklische Analoge von alpha-MSH-Fragmenten mit ausserordentlicher Wirkung.
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
DE19931310A1 (de) * 1999-07-07 2001-01-11 Beiersdorf Ag Verwendung von Phospholipiden zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Vertärkung der natürlichen Hautbräunung bzw. zur Stimulierung der Melanogenese der menschlichen Haut

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004623A1 (fr) * 1986-02-03 1987-08-13 University Patents, Inc. Procede de stimulation de melanocytes par l'application topique d'analogues d'alpha-msh, et compositions utilisees
US5674839A (en) * 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
EP0386680A1 (fr) * 1989-03-07 1990-09-12 Plough, Inc. Compositions à base de liposomes
US5641509A (en) * 1992-06-26 1997-06-24 Lancaster Group Ag Preparation for topical use
WO2000004873A1 (fr) * 1998-07-22 2000-02-03 Smith & Nephew Plc Compositions dermatologiques pour le traitement de cicatrices

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DORR R T ET AL: "EVALUATION OF MELANOTAN-II, A SUPERPOTENT CYCLIC MELANOTROPIC PEPTIDE IN A PILOT PHASE-I CLINICAL STUDY", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 58, no. 20, 1996, pages 1777 - 1784, XP001079873, ISSN: 0024-3205 *
HADLEY M E ET AL: "DISCOVERY AND DEVELOPMENT OF NOVEL MELANOGENIC DRUGS//MELANOTAN-I AND -II", INTEGRATION OF PHARMACEUTICAL DISCOVERY AND DEVELOPMENTS: CASE STUDIES, XX, XX, 1998, pages 575 - 595, XP001064545 *
PAWELEK JOHN M: "Approaches to increasing skin melanin with MSH Analogs and synthetic melanins", PIGMENT CELL RESEARCH, vol. 14, no. 3, 14 January 2001 (2001-01-14), pages 155 - 160, XP002255862 *

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1812034A1 (fr) * 2004-10-08 2007-08-01 Clinuvel Pharmaceuticals Limited Prépaprations et méthodes permettant d'induire la mélanogenèse chez un sujet
EP1812034A4 (fr) * 2004-10-08 2009-07-29 Clinuvel Pharmaceuticals Ltd Prépaprations et méthodes permettant d'induire la mélanogenèse chez un sujet
EP2368562A1 (fr) * 2004-10-08 2011-09-28 Clinuvel Pharmaceuticals Limited Compositions et procédés pour induire la mélanogenèse chez un sujet
EP2939686A1 (fr) * 2004-10-08 2015-11-04 Clinuvel Pharmaceuticals Limited Compositions et procédés pour induire la mélanogenèse chez un sujet
WO2009124754A1 (fr) * 2008-04-08 2009-10-15 Merck Patent Gmbh Compositions contenant des peptides cycliques et leurs procédés d’utilisation
US20110027209A1 (en) * 2008-04-08 2011-02-03 Merck Patent Gesellschaft Compositions Containing Cyclic Peptides And Methods Of Use
RU2555357C2 (ru) * 2008-04-08 2015-07-10 Мерк Патент Гмбх Композиции, содержащие циклические пептиды, и способы их применения
US10278911B2 (en) 2008-04-08 2019-05-07 Merck Patent Gmbh Compositions containing cyclic peptides and methods of use
WO2014160015A1 (fr) * 2013-03-13 2014-10-02 Transdermal Biotechnology, Inc. Compositions pour le bronzage de la peau contenant des peptides et autres compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9439926B2 (en) 2013-03-13 2016-09-13 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9480642B2 (en) 2013-03-13 2016-11-01 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9498535B2 (en) 2013-03-13 2016-11-22 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9585817B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9585829B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9585931B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9597401B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9597400B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9636291B2 (en) 2013-03-13 2017-05-02 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9682102B2 (en) 2013-03-13 2017-06-20 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9687504B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9694083B2 (en) 2013-03-13 2017-07-04 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9694029B2 (en) 2013-03-13 2017-07-04 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9700626B2 (en) 2013-03-13 2017-07-11 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9717680B2 (en) 2013-03-13 2017-08-01 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9757467B2 (en) 2013-03-13 2017-09-12 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9827316B2 (en) 2013-03-13 2017-11-28 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9844506B2 (en) 2013-03-13 2017-12-19 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9872818B2 (en) 2013-03-13 2018-01-23 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9913793B2 (en) 2013-03-13 2018-03-13 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9931370B2 (en) 2013-03-13 2018-04-03 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9937221B2 (en) 2013-03-13 2018-04-10 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9943562B2 (en) 2013-03-13 2018-04-17 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9956290B2 (en) 2013-03-13 2018-05-01 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US10028994B2 (en) 2013-03-13 2018-07-24 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US10034914B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US10034828B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US10034944B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US10064955B2 (en) 2013-03-13 2018-09-04 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US10071117B2 (en) 2013-03-13 2018-09-11 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US10080768B2 (en) 2013-03-13 2018-09-25 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US10155048B2 (en) 2013-03-13 2018-12-18 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US10188603B2 (en) 2013-03-13 2019-01-29 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US10213457B2 (en) 2013-03-13 2019-02-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US10226511B2 (en) 2013-03-13 2019-03-12 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions

Also Published As

Publication number Publication date
DE10228837B4 (de) 2016-01-07
AU2003246597A1 (en) 2004-01-19
DE10228837A1 (de) 2004-01-15

Similar Documents

Publication Publication Date Title
DE10228837B4 (de) Hautkosmetische Zusammensetzung und Verwendung der Zusammensetzung als Hautbräunungsmittel
DE60104423T2 (de) Neue verbindungen der familie von n-acylaminoamiden, sie enthaltende zusammensetzungen und verwendungen
DE60306565T2 (de) Zusammensetzungen gegen Krebs zur topischen Anwendung
DE60023816T2 (de) Verwendung von Lycopin in Zusammensetzungen zur Behandlung von Hautalterungserscheinungen
EP1014925A1 (fr) Combinaison d'erythrulose et d'un sucre reducteur presentant un effet autobronzant
DE69819006T2 (de) Verwendung von ginsenoside rb1 zur stimulierung der elastinsynthese
DE4100975A1 (de) Kosmetische oder pharmazeutische zubereitungen zur verbesserung der haarqualitaet und foerderung des haarwachstums
DE3010572A1 (de) Hautpflege- und hautschutzpraeparate
CH697417B1 (de) Mittel zur Behandlung der Hautalterung enthaltend Paeoniflorin.
EP1100456A1 (fr) Utilisation d'ectoine ou de derives d'ectoine dans des formulations cosmetiques
DE69720613T2 (de) Neue topische Zusammensetzungen, die Melatonin oder seine Analogen in sehr niedrigen Dosen enthalten, und ihre Verwendung in der Kosmetik
DE60122973T2 (de) Mittel, insbesondere für Kosmetika, enthaltend DHEA und/oder Vorstufe oder Derivate davon, und mindestens eine Verbindung, die die Glykosaminoglykane-Synthese erhöht
DE69600871T3 (de) Filtrierende Zusammensetzung für die kosmetische oder dermatologische Verwendung, die einen Chelat-Bildner für Eisen enthält
WO2000015187A1 (fr) Creatine et/ou derives de creatine utilises comme preparations cosmetiques contenant des agents de maintien d'humidification
WO2002098380A1 (fr) Preparation destinee a eliminer la matiere keratinique anormale
DE3615396A1 (de) Mittel zur behandlung der haare und der kopfhaut
DE3029263A1 (de) Kosmetisches praeparat
DE60105617T2 (de) Zusammensetzung und insbesondere kosmetische Zusammensetzung , die DHEA und/oder einen Vorläufer oder ein Derivat von DHEA in Kombination mit mindestens einem Wirkstoff gegen Glykation enthält
DE1149858B (de) Haut- und Haarpflegemittel
WO2011131441A1 (fr) Combinaisons de principes actifs d'extrait d'écorce de magnolia et d'agents tensioactifs (polyglycéryl (3)-méthylglucosedistéarate)
DE2757024C3 (de) Kosmetisches Haar- und Hautpflegemittel
DE3435842C2 (fr)
EP0016239B1 (fr) Préparation cosmétique pour la peau et les cheveux et sa fabrication
DE69937799T2 (de) Neue anwendungsgebiete von ascorbyl-phosphoryl-cholesterol und zubereitungen, um diese umzusetzen
DE2749960A1 (de) Kosmetische mittel

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP